FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765434048> ?p ?o ?g. }

• W2765434048 abstract "Data from clinical trials suggest that polyethylene glycol-conjugated asparaginase (PEG asparaginase) should be recommended as a replacement for Escherichia coli (E. coli) asparaginase in the treatment of pediatric acute lymphoblastic leukemia (ALL) due to its prolonged effect, similar safety profile and convenience. The present study investigated the efficacy and safety of PEG asparaginase in adolescents and adults with newly diagnosed ALL. The clinical data of 122 patients, ≥14 years old with de novo ALL, who received either PEG asparaginase or E. coli asparaginase as part of an induction regimen, were retrospectively analyzed. The results revealed that PEG asparaginase had a comparable complete remission rate (95.65 vs. 90.79%), median overall survival time (14.07 vs. 16.29 months) and median relapse-free survival time (10.00 vs. 8.57 months) with E. coli asparaginase. In addition, patients <35 years old receiving PEG asparaginase obtained a higher median RFS time compared with those receiving E. coli asparaginase (10.93 vs. 8.97 months; P=0.037). Patients treated with E. coli asparaginase exhibited a significantly higher incidence of central nervous system leukemia (CNSL) compared with those treated with PEG asparaginase (27.63 vs. 10.87%; P=0.028) during the consolidation phase. Toxic events, including allergy, grade III-IV liver dysfunction, renal function damage and pancreatic lesions were similar between the two groups. A longer duration of coagulation dysfunction (9.80±5.51 vs. 6.80±4.21 days; P=0.002) and agranulocytosis (18.89±8.79 vs. 12.03±8.34 days; P<0.01), and a higher incidence of grade IV-V infections (22.73 vs. 7.25%; P=0.018) were observed in the PEG asparaginase group. However, these did not increase bleeding events or infection-associated mortalities. When taking the convenience and superior efficacy in preventing CNSL into consideration, PEG asparaginase is a candidate for first-line treatment of adolescent and adult ALL. A larger prospective clinical trial is required to further confirm this point of view." @default.
• W2765434048 created "2017-11-10" @default.
• W2765434048 creator A5004958903 @default.
• W2765434048 creator A5018722248 @default.
• W2765434048 creator A5025530232 @default.
• W2765434048 creator A5028097742 @default.
• W2765434048 creator A5040721399 @default.
• W2765434048 creator A5041183580 @default.
• W2765434048 creator A5053447705 @default.
• W2765434048 creator A5061410812 @default.
• W2765434048 creator A5075699837 @default.
• W2765434048 creator A5084846616 @default.
• W2765434048 date "2017-10-26" @default.
• W2765434048 modified "2023-10-01" @default.
• W2765434048 title "A retrospective comparison of Escherichia�coli and polyethylene glycol‑conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia" @default.
• W2765434048 cites W1965542498 @default.
• W2765434048 cites W1978731039 @default.
• W2765434048 cites W2002189121 @default.
• W2765434048 cites W2007348709 @default.
• W2765434048 cites W2010729137 @default.
• W2765434048 cites W2017265604 @default.
• W2765434048 cites W2037808957 @default.
• W2765434048 cites W2038931075 @default.
• W2765434048 cites W2053852136 @default.
• W2765434048 cites W2056302309 @default.
• W2765434048 cites W2056638982 @default.
• W2765434048 cites W2068619849 @default.
• W2765434048 cites W2069643559 @default.
• W2765434048 cites W2084089666 @default.
• W2765434048 cites W2098292727 @default.
• W2765434048 cites W2106275447 @default.
• W2765434048 cites W2109139880 @default.
• W2765434048 cites W2113512182 @default.
• W2765434048 cites W2117623554 @default.
• W2765434048 cites W2127153931 @default.
• W2765434048 cites W2146971143 @default.
• W2765434048 cites W2151477149 @default.
• W2765434048 cites W2162448677 @default.
• W2765434048 cites W2163219205 @default.
• W2765434048 cites W2164520862 @default.
• W2765434048 cites W2169732420 @default.
• W2765434048 cites W2209016636 @default.
• W2765434048 cites W613788174 @default.
• W2765434048 cites W98666424 @default.
• W2765434048 doi "https://doi.org/10.3892/ol.2017.7271" @default.
• W2765434048 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5769219" @default.
• W2765434048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29387211" @default.
• W2765434048 hasPublicationYear "2017" @default.
• W2765434048 type Work @default.
• W2765434048 sameAs 2765434048 @default.
• W2765434048 citedByCount "4" @default.
• W2765434048 countsByYear W27654340482018 @default.
• W2765434048 countsByYear W27654340482019 @default.
• W2765434048 countsByYear W27654340482020 @default.
• W2765434048 countsByYear W27654340482023 @default.
• W2765434048 crossrefType "journal-article" @default.
• W2765434048 hasAuthorship W2765434048A5004958903 @default.
• W2765434048 hasAuthorship W2765434048A5018722248 @default.
• W2765434048 hasAuthorship W2765434048A5025530232 @default.
• W2765434048 hasAuthorship W2765434048A5028097742 @default.
• W2765434048 hasAuthorship W2765434048A5040721399 @default.
• W2765434048 hasAuthorship W2765434048A5041183580 @default.
• W2765434048 hasAuthorship W2765434048A5053447705 @default.
• W2765434048 hasAuthorship W2765434048A5061410812 @default.
• W2765434048 hasAuthorship W2765434048A5075699837 @default.
• W2765434048 hasAuthorship W2765434048A5084846616 @default.
• W2765434048 hasBestOaLocation W27654340481 @default.
• W2765434048 hasConcept C10138342 @default.
• W2765434048 hasConcept C126322002 @default.
• W2765434048 hasConcept C141071460 @default.
• W2765434048 hasConcept C162324750 @default.
• W2765434048 hasConcept C2778461978 @default.
• W2765434048 hasConcept C2778904437 @default.
• W2765434048 hasConcept C2909962599 @default.
• W2765434048 hasConcept C54400483 @default.
• W2765434048 hasConcept C71924100 @default.
• W2765434048 hasConcept C90924648 @default.
• W2765434048 hasConceptScore W2765434048C10138342 @default.
• W2765434048 hasConceptScore W2765434048C126322002 @default.
• W2765434048 hasConceptScore W2765434048C141071460 @default.
• W2765434048 hasConceptScore W2765434048C162324750 @default.
• W2765434048 hasConceptScore W2765434048C2778461978 @default.
• W2765434048 hasConceptScore W2765434048C2778904437 @default.
• W2765434048 hasConceptScore W2765434048C2909962599 @default.
• W2765434048 hasConceptScore W2765434048C54400483 @default.
• W2765434048 hasConceptScore W2765434048C71924100 @default.
• W2765434048 hasConceptScore W2765434048C90924648 @default.
• W2765434048 hasLocation W27654340481 @default.
• W2765434048 hasLocation W27654340482 @default.
• W2765434048 hasLocation W27654340483 @default.
• W2765434048 hasLocation W27654340484 @default.
• W2765434048 hasOpenAccess W2765434048 @default.
• W2765434048 hasPrimaryLocation W27654340481 @default.
• W2765434048 hasRelatedWork W1994073090 @default.
• W2765434048 hasRelatedWork W2391172627 @default.
• W2765434048 hasRelatedWork W2399260484 @default.
• W2765434048 hasRelatedWork W2889208794 @default.
• W2765434048 hasRelatedWork W2890594313 @default.
• W2765434048 hasRelatedWork W2971986391 @default.
• W2765434048 hasRelatedWork W3199199840 @default.

• next